Strong synergistic effects were detected in both TP53 wild type and TP53 mutant AML cell lines treated with PTC596 in combination with the MCL1 inhibitor S63845 or the MEK-inhibitor trametinib. Here, MCL1 is linked to acute myeloid leukemia.